Fengming Liu1, Lin Wu2, Gongxiong Wu3, Chun Wang4, Lining Zhang5, Stephen Tomlinson6, Xuebin Qin7. 1. Department of Immunology, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China; Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Department of Neuroscience, Temple University School of Medicine, Philadelphia, PA 19140, USA. 2. Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Department of Hematology, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai 200080, PR China. 3. Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. 4. Department of Hematology, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai 200080, PR China. 5. Department of Immunology, Shandong University School of Medicine, #44 Wenhua Xi Road, Jinan, Shandong 250012, PR China. 6. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA; Ralph A. Johnson Veterans Affairs Medical Center, Charleston, SC 29401, USA. Electronic address: tomlinss@musc.edu. 7. Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Department of Neuroscience, Temple University School of Medicine, Philadelphia, PA 19140, USA. Electronic address: xuebin.qin@temple.edu.
Abstract
OBJECTIVE: Atherosclerosis is a chronic inflammatory and immune vascular disease, and clinical and experimental evidence has indicated an important role of complement activation products, including the terminal membrane attack complex (MAC), in atherogenesis. Here, we investigated whether complement inhibition represents a potential therapeutic strategy to treat/prevent atherogenesis using CR2-Crry, a recently described complement inhibitor that specifically targets to sites of C3 activation. METHODS AND RESULTS: Previous studies demonstrated that loss of CD59 (a membrane inhibitor of MAC formation) accelerated atherogenesis in Apoe deficient (Apoe(-/-)) mice. Here, both CD59 sufficient and CD59 deficient mice in an Apoe deficient background (namely, mCd59 ab(+/+)/Apoe(-/-) and mCd59 ab(-/-)/Apoe(-/-)) were treated with CR2-Crry for 4 and 2 months respectively, while maintained on a high fat diet. Compared to control treatment, CR2-Crry treatment resulted in significantly fewer atherosclerotic lesions in the aorta and aortic root, and inhibited the accelerated atherogenesis seen in mCd59 ab(+/+)/Apoe(-/-) and mCd59 ab(-/-)/Apoe(-/-) mice. CR2-Crry treatment also resulted in significantly reduced C3 and MAC deposition in the vasculature of both mice, as well as a significant reduction in the number of infiltrating macrophages and T cells. CONCLUSION: The data demonstrate the therapeutic potential of targeted complement inhibition.
OBJECTIVE:Atherosclerosis is a chronic inflammatory and immune vascular disease, and clinical and experimental evidence has indicated an important role of complement activation products, including the terminal membrane attack complex (MAC), in atherogenesis. Here, we investigated whether complement inhibition represents a potential therapeutic strategy to treat/prevent atherogenesis using CR2-Crry, a recently described complement inhibitor that specifically targets to sites of C3 activation. METHODS AND RESULTS: Previous studies demonstrated that loss of CD59 (a membrane inhibitor of MAC formation) accelerated atherogenesis in Apoe deficient (Apoe(-/-)) mice. Here, both CD59 sufficient and CD59 deficient mice in an Apoe deficient background (namely, mCd59 ab(+/+)/Apoe(-/-) and mCd59 ab(-/-)/Apoe(-/-)) were treated with CR2-Crry for 4 and 2 months respectively, while maintained on a high fat diet. Compared to control treatment, CR2-Crry treatment resulted in significantly fewer atherosclerotic lesions in the aorta and aortic root, and inhibited the accelerated atherogenesis seen in mCd59 ab(+/+)/Apoe(-/-) and mCd59 ab(-/-)/Apoe(-/-) mice. CR2-Crry treatment also resulted in significantly reduced C3 and MAC deposition in the vasculature of both mice, as well as a significant reduction in the number of infiltrating macrophages and T cells. CONCLUSION: The data demonstrate the therapeutic potential of targeted complement inhibition.
Authors: X Qin; T Miwa; H Aktas; M Gao; C Lee; Y M Qian; C C Morton; A Shahsafaei; W C Song; J A Halperin Journal: Mamm Genome Date: 2001-08 Impact factor: 2.957
Authors: M E Medof; D M Lublin; V M Holers; D J Ayers; R R Getty; J F Leykam; J P Atkinson; M L Tykocinski Journal: Proc Natl Acad Sci U S A Date: 1987-04 Impact factor: 11.205
Authors: Ruth D Lewis; Mark J Perry; Irina A Guschina; Christopher L Jackson; B Paul Morgan; Timothy R Hughes Journal: Am J Pathol Date: 2011-08-02 Impact factor: 4.307
Authors: Sonia I Vlaicu; Alexandru Tatomir; Violeta Rus; Armugam P Mekala; Petru A Mircea; Florin Niculescu; Horea Rus Journal: Immunol Res Date: 2016-02 Impact factor: 2.829
Authors: Shen Dai; Fengming Liu; Mi Ren; Zhongnan Qin; Namita Rout; Xiao-Feng Yang; Hong Wang; Stephen Tomlinson; Xuebin Qin Journal: Front Cardiovasc Med Date: 2021-09-28
Authors: Nirmal K Banda; Stephen Tomlinson; Robert I Scheinman; Nhu Ho; Joseline Ramos Ramirez; Gaurav Mehta; Guankui Wang; Vivian Pham Vu; Dmitri Simberg; Liudmila Kulik; V Michael Holers Journal: Front Immunol Date: 2020-10-16 Impact factor: 7.561